Ribonuclease H/DNA polymerase HIV-1 reverse transcriptase dual inhibitor: Mechanistic studies on the allosteric mode of action of isatin-based compound RMNC6

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Corona, Angela ^a   Meleddu, Rita ^a   Esposito, Francesca ^a   Distinto, Simona ^a   Bianco, Giulia ^a   Masaoka, Takashi ^b   Maccioni, Elias ^a   Menéndez Arias, Luis ^c   Alcaro, Stefano ^d   Le Grice, Stuart F J ^b   Tramontano, Enzo ^a,e  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Milan Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4-(2-(2-(2-OXOINDOLIN-3-YLIDENE)HYDRAZINYL)THIAZOL-4-YL)BENZONITRILE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; EFAVIRENZ; ENZYME INHIBITOR; HYDRAZONE DERIVATIVE; ISATIN; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL SENSITIVITY TEST; MOLECULAR DOCKING; PROTEIN TERTIARY STRUCTURE; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZOXAZINES; BINDING SITES; ENZYME INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; HYDRAZONES; ISATIN; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84958212843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147225     Document Type: Article

References (56)

1. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220:868-71. PMID: 6189183
2. Broder S, Gallo RC. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med. 1984; 311:1292-7. PMID: 6208484
3. Schatz O, Cromme F, Naas T, Lindemann D. Inactivation of the RNase H domain of HIV-1 reverse transcriptase blocks viral infectivity. Gene Regul AIDS. 1990; Oncogenesis and AIDS. Papas TS(Ed.). Portfolio Publishing Company;: 293-404.
4. Shaw-Reid C a, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, et al. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry. 2005; 44:1595-606. PMID: 15683243
5. Menéndez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008; 134:124-46. doi: 10.1016/j.virusres.2007.12.015 PMID: 18272247
6. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara R a. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J Biol Chem. 1997; 272:11157-64. PMID: 9111014
7. Hizi A, McGill C, Hughes S. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A. 1988; 85:1218-22. PMID: 2448794
8. Gopalakrishnan V, Peliska J a, Benkovic SJ. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc Natl Acad Sci U S A. 1992; 89:10763-7. PMID: 1279694
9. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol. 2007; 81:7852-9. PMID: 17507476
10. Roquebert B, Marcelin A-G. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother. 2008; 61:973-5. doi: 10.1093/jac/dkn060 PMID: 18325896
11. Herman BD, Sluis-Cremer N. Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a β-thujaplicinol analogue. Biochem J. 2013; 455:179-84. doi: 10.1042/BJ20130850 PMID: 23927736
12. Betancor G, Álvarez M, Marcelli B, Andrés C, Martínez MA, Menéndez-Arias L. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis. Nucleic Acids Res. 2015; 43:2259-70. doi: 10.1093/nar/gkv077 PMID: 25662223
13. Frentz D, Van de Vijver DAMC, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014; 14:407. doi: 10.1186/1471-2334-14-407 PMID: 25047543
14. Esposito F, Corona A, Tramontano E. HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. Mol Biol Int. 2012; 2012:586401. doi: 10.1155/2012/586401 PMID: 22778958
15. Corona A, Masaoka T, Tocco G, Grice Stuart FJ, Tramontano E. Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase. Futur Med Chem. 2013; 5:2127-39.
16. Corona A, Esposito F, Tramontano E. Can the ever-promising target HIV reverse transcriptase-associated RNase H become a success story for drug development? Future Virol. 2014; 9:445-8.
17. Vernekar SK V, Liu Z, Nagy E, Miller L, Kirby KA, Wilson DJ, et al. Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1, 3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities. J Med Chem. 2015; 58:651-64. doi: 10.1021/jm501132s PMID: 25522204
18. Distinto S, Maccioni E, Meleddu R, Corona A, Alcaro S, Tramontano E. Molecular Aspects of the RT/ drug Interactions. Perspective of Dual Inhibitors. Curr Pharm Des. 2013; 19:1850-9. PMID: 23092286
19. Himmel DM, Sarafianos SG, Dharmasena S, Hossain MM, McCoy-Simandle K, Ilina T, et al. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol. 2006; 1:702-12. PMID: 17184135
20. Felts AK, Labarge K, Bauman JD, Patel D V, Himmel DM, Arnold E, et al. Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model. 2011; 51:1986-98. doi: 10.1021/ci200194w PMID: 21714567
21. Gong Q, Menon L, Ilina T, Miller LG, Ahn J, Parniak M a, et al. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem Biol Drug Des. 2011; 77:39-47. doi: 10.1111/j. 1747-0285.2010.01052.x PMID: 21114787
22. Christen MT, Menon L, Myshakina NS, Ahn J, Parniak MA, Ishima R. Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain. Chem Biol Drug Des. 2012; 80:706-16. doi: 10.1111/cbdd.12010 PMID: 22846652
23. Distinto S, Esposito F, Kirchmair J, Cardia MC, Gaspari M, Maccioni E, et al. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint-and pharmacophore-based virtual screening approach. Eur J Med Chem. 2012; 50:216-29. doi: 10.1016/j.ejmech.2012.01.056 PMID: 22361685
24. Meleddu R, Distinto S, Corona A, Bianco G, Cannas V, Esposito F, et al. (3Z)-3-(2-[4-(aryl)-1, 3-thiazol-2-yl]hydrazin-1-ylidene)-2, 3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase. Eur J Med Chem. 2015; 93:452-60. doi: 10.1016/j.ejmech.2015.02.032 PMID: 25728026
25. Le Grice SF, Cameron CE, Benkovic SJ. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 1995; 262:130-44. PMID: 8594344
26. Alvarez M, Matamoros T, Menéndez-Arias L. Increased thermostability and fidelity of DNA synthesis of wild-type and mutant HIV-1 group O reverse transcriptases. J Mol Biol. 2009; 392:872-84. doi:10.1016/j.jmb.2009.07.081 PMID: 19651140
27. Álvarez M, Barrioluengo V, Afonso-Lehmann RN, Menéndez-Arias L. Altered error specificity of RNase H-deficient HIV-1 reverse transcriptases during DNA-dependent DNA synthesis. Nucleic Acids Res. 2013; 41:4601-12. doi: 10.1093/nar/gkt109 PMID: 23444139
28. Meleddu R, Cannas V, Distinto S, Sarais G, Del Vecchio C, Esposito F, et al. Design, synthesis, and biological evaluation of 1, 3-diarylpropenones as dual inhibitors of HIV-1 reverse transcriptase. Chem-MedChem. 2014; 9:1869-79. doi: 10.1002/cmdc.201402015 PMID: 24850787
29. Xu L, Grandi N, Del Vecchio C, Mandas D, Corona A, Piano D, et al. From the traditional Chinese medicine plant Schisandra chinensis new scaffolds effective on HIV-1 reverse transcriptase resistant to non-nucleoside inhibitors. J Microbiol. 2015
30. Yonetani T. The Yonetani-Theorell graphical method for examining overlapping subsites of enzyme active centers. Methods Enzymol. 1982; 87:500-9. PMID: 6757651
31. Esposito F, Kharlamova T, Distinto S, Zinzula L, Cheng Y-C, Dutschman G, et al. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. FEBS J. 2011; 278:1444-57. doi: 10.1111/j.1742-4658.2011.08057.x PMID: 21348941
32. Corona A, Di Leva FS, Thierry S, Pescatori L, Cuzzucoli Crucitti G, Subra F, et al. Identification of Highly Conserved Residues Involved in Inhibition of HIV-1 RNase H Function by Diketo Acid Derivatives. Antimicrob Agents Chemother. 2014; 58:6101-10. doi: 10.1128/AAC.03605-14 PMID: 25092689
33. Nettleship JE, Brown J, Groves MR, Geerlof A. Methods for protein characterization by mass spectrometry, thermal shift (ThermoFluor) assay, and multiangle or static light scattering. Methods Mol Biol. 2008; 426:299-318. doi: 10.1007/978-1-60327-058-8-19 PMID: 18542872
34. Halgren TA. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem. 1996; 17:520-52.
35. Hasel W, Hendrickson TF, Still WC. Tetrahedron Computer Methodology. Tetrahedron Comput Methodol. 1988; 1:103-16.
36. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28:235-42. PMID: 10592235
37. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol. 1995; 2:293-302. PMID: 7540934
38. Das K, Bauman JD, Clark AD, Frenkel Y V, Lewi PJ, Shatkin AJ, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A. 2008; 105:1466-71. doi: 10.1073/pnas.0711209105 PMID: 18230722
39. Ren J. Binding of the Second Generation Non-nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding. J Biol Chem. 2000; 275:14316-20. PMID: 10799511
40. Das K, Bauman JD, Rim AS, Dharia C, Clark AD, Camarasa M-J, et al. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem. 2011; 54:2727-37. doi: 10.1021/jm101536x PMID: 21446702
41. Pata JD, Stirtan WG, Goldstein SW, Steitz T a. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 2004; 101:10548-53. PMID: 15249669
42. Himmel DM, Maegley K a, Pauly T a, Bauman JD, Das K, Dharia C, et al. Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure. 2009; 17:1625-35. doi: 10.1016/j.str.2009.09.016 PMID: 20004166
43. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides. J Phys Chem B. 2001; 105:6474-87.
44. Cho AE, Guallar V, Berne BJ, Friesner R. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. J Comput Chem. 2005; 26:915-31. PMID: 15841474
45. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000; 33:889-97. PMID: 11123888
46. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1Hpyrrol-2-yl)]-2, 4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 2005; 65:117-24. PMID: 15708638
47. Masaoka T, Chung S, Caboni P, Rausch JW, Wilson JA, Taskent-Sezgin H, et al. Exploiting Drug-Resistant Enzymes as Tools To Identify Thienopyrimidinone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. J Med Chem. 2013; 56:5436-45. doi:10.1021/jm400405z PMID: 23631411
48. Cummings MD, Farnum M a, Nelen MI. Universal screening methods and applications of ThermoFluor. J Biomol Screen. 2006; 11:854-63. PMID: 16943390
49. Chung S, Miller JT, Johnson BC, Hughes SH, Le Grice SFJ. Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J Biol Chem. 2012; 287:4066-75. doi: 10.1074/jbc.M111.314781 PMID: 22105069
50. Su H-P, Yan Y, Prasad GS, Smith RF, Daniels CL, Abeywickrema PD, et al. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol. 2010; 84:7625-33. doi: 10.1128/JVI.00353-10 PMID: 20484498
51. Quiñones-Mateu ME, Soriano V, Domingo E, Menéndez-Arias L. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology. 1997; 236:364-73. PMID: 9325244
52. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak M a, et al. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res. 2005; 33:1249-56. PMID: 15741178
53. Paris KA, Haq O, Felts AK, Das K, Arnold E, Levy RM. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. J Med Chem. 2009; 52:6413-20. doi: 10.1021/jm900854h PMID: 19827836
54. Jacobo-Molina A, Ding J, Nanni RG, Clark AD, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90:6320-4. PMID: 7687065
55. Julias JG, McWilliams MJ, Sarafianos SG, Arnold E, Hughes SH. Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci U S A. 2002; 99:9515-20. PMID: 12093908
56. Rausch JW, Lener D, Miller JT, Julias JG, Hughes SH, Le Grice SFJ. Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry. 2002; 41:4856-65. PMID: 11939780